amlexanox has been researched along with Inflammation in 8 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amlexanox has also been legally utilized and administered in Japan as a treatment for asthma, a chronic pulmonary disease characterized by inflammation of the lower respiratory tract." | 2.66 | Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease. ( Dosanjh, A; Won, CY, 2020) |
| "These effects were mediated by the breast cancer oncogene IKKε and its downstream target-the serine biosynthesis pathway as demonstrated by genetic or pharmacological tools." | 1.56 | Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway. ( Bentham, RB; Bianchi, K; Carter, E; Dalli, J; Godinho, SA; Grose, R; Hodivala-Dilke, K; Holdsworth, J; Ironside, A; Jones, L; Jones, W; Mataloni, I; Moreno Béjar, R; Szabadkai, G; Uhlik, L; Wilcz-Villega, E; Xu, R, 2020) |
| "Chronic low-grade inflammation is a hallmark of obesity, which is a risk factor for the development of type 2 diabetes." | 1.48 | Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK ( Beyett, TS; Chang, L; Gan, X; Gomez, AV; Reilly, SM; Saltiel, AR; Showalter, HD; Tesmer, JJG, 2018) |
| "Olopatadine hydrochloride (olopatadine) is an antiallergic drug with histamine H(1) receptor antagonistic activity." | 1.33 | Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. ( Hasegawa, K; Kaneko, S; Kishimoto, K; Ohmori, K; Tamura, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, Z | 1 |
| Qi, J | 1 |
| Zhao, J | 1 |
| Lim, CW | 1 |
| Kim, JW | 1 |
| Kim, B | 1 |
| Wilcz-Villega, E | 1 |
| Carter, E | 1 |
| Ironside, A | 1 |
| Xu, R | 1 |
| Mataloni, I | 1 |
| Holdsworth, J | 1 |
| Jones, W | 1 |
| Moreno Béjar, R | 1 |
| Uhlik, L | 1 |
| Bentham, RB | 1 |
| Godinho, SA | 1 |
| Dalli, J | 1 |
| Grose, R | 1 |
| Szabadkai, G | 1 |
| Jones, L | 1 |
| Hodivala-Dilke, K | 1 |
| Bianchi, K | 1 |
| Han, Y | 1 |
| Hou, R | 1 |
| Zhang, X | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Li, X | 1 |
| Qi, R | 1 |
| Cai, R | 1 |
| Qi, Y | 1 |
| Dosanjh, A | 1 |
| Won, CY | 1 |
| Beyett, TS | 1 |
| Gan, X | 1 |
| Reilly, SM | 3 |
| Chang, L | 3 |
| Gomez, AV | 1 |
| Saltiel, AR | 3 |
| Showalter, HD | 1 |
| Tesmer, JJG | 1 |
| Mowers, J | 1 |
| Uhm, M | 2 |
| Simon, J | 1 |
| Leto, D | 1 |
| Chiang, SH | 1 |
| Ahmadian, M | 1 |
| Zamarron, BF | 1 |
| Poirier, B | 1 |
| Peng, X | 1 |
| Krause, DM | 1 |
| Korytnaya, E | 1 |
| Neidert, A | 1 |
| Liddle, C | 1 |
| Yu, RT | 1 |
| Lumeng, CN | 1 |
| Oral, EA | 1 |
| Downes, M | 1 |
| Evans, RM | 1 |
| Kishimoto, K | 1 |
| Kaneko, S | 1 |
| Ohmori, K | 1 |
| Tamura, T | 1 |
| Hasegawa, K | 1 |
1 review available for amlexanox and Inflammation
| Article | Year |
|---|---|
Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease.
Topics: Aminopyridines; Animals; Anti-Allergic Agents; Asthma; Humans; Hypersensitivity, Immediate; Inflamma | 2020 |
1 trial available for amlexanox and Inflammation
| Article | Year |
|---|---|
A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Aged; Aminopyridines; Animals; Cyclic AMP; Female; Gene Knockdown T | 2015 |
6 other studies available for amlexanox and Inflammation
| Article | Year |
|---|---|
Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice.
Topics: Aminopyridines; Animals; Bile Ducts; Carbon Tetrachloride; Hepatic Stellate Cells; I-kappa B Kinase; | 2020 |
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.
Topics: Aminopyridines; Animals; Breast Neoplasms; Culture Media, Conditioned; Epithelial Cells; Female; Hum | 2020 |
Amlexanox exerts anti-inflammatory actions by targeting phosphodiesterase 4B in lipopolysaccharide-activated macrophages.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, | 2020 |
Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Topics: 3T3-L1 Cells; Adipocytes; Aminopyridines; Animals; Carboxylic Acids; Cell Line; Diabetes Mellitus, T | 2018 |
Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Adrenergic beta-3 Receptor Agonists; Aminopyridines | 2013 |
Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.
Topics: Aminopyridines; Cell Culture Techniques; Cell Movement; Dibenzoxepins; Gene Expression Regulation; H | 2006 |